Holotranscobalamin (Active B12)

What is Holotranscobalamin (Active B12)?

Holotranscobalamin, often called active B12, measures only the fraction of blood B12 attached to transcobalamin, the protein that carries B12 into your cells.

Vitamin B12 in your blood doesn't float around freely. It travels attached to one of two carrier proteins, and this is the detail that makes holotranscobalamin its own distinct test rather than a repackaged version of total B12. The first carrier is transcobalamin. B12 attached to transcobalamin, called holotranscobalamin, is the fraction your cells can actually take up, because transcobalamin is the protein that cell-surface receptors recognize and use to pull B12 inside. The second carrier is haptocorrin. According to a 2024 review by Nexo and Parkner in Advances in Clinical Chemistry, haptocorrin carries roughly three-quarters of circulating B12, and there is no evidence that B12 from holo-haptocorrin contributes to B12 status, per a 2025 review in Annals of Clinical Biochemistry by Harrington, Stevenson, and Sobczyńska-Malefora. A standard total B12 test adds both fractions together and can't tell you how much of that number is the haptocorrin-bound majority that your cells never touch. This is the practical reason holotranscobalamin exists as a separate test: two people can have the same total B12 result while one of them has a normal transcobalamin fraction and the other has very little. The Harrington 2025 review notes that because haptocorrin makes up most of what a total B12 assay reports, total B12 lags as an indicator, while holotranscobalamin more directly reflects newly absorbed B12 available for use. That biochemistry is also why holotranscobalamin gets used differently depending on where you're tested. In the UK, the NICE guideline on vitamin B12 deficiency in adults (NG239, published March 6, 2024) allows either total B12 or active B12 as a first-line test, and specifically recommends active B12 for pregnant and breastfeeding people, because haptocorrin production drops during pregnancy and pulls total B12 down without reflecting a true deficiency. In the US, total B12 remains the default first test in most settings, and holotranscobalamin is typically ordered as a second-line or confirmatory test when a total B12 result sits in an ambiguous range. In some places it isn't available through standard lab panels at all. One example of how narrowly this test is sometimes deployed: at least one UK NHS trust runs active B12 only for pregnant patients and won't process the request for anyone else through its standard ordering system, reflecting how the test's clinical use, in practice, is still narrower than total B12's.

Typical reference context

Source: Harrington, Stevenson, and Sobczyńska-Malefora, "The application and interpretation of laboratory biomarkers for the evaluation of vitamin B12 status," Annals of Clinical Biochemistry, 2025, and consistent with UK NHS trust lab reference ranges (Gloucestershire Hospitals NHS Foundation Trust). Cutoffs vary by assay platform and lab, so always read your own report's stated reference range alongside the number, not this table.

What changed recently

The NICE guideline (NG239, March 2024) formally reviewed holotranscobalamin's diagnostic accuracy and found the underlying evidence weak: the committee looked at six studies and rated the evidence "very low quality," partly because no two studies used the same reference standard for defining deficiency. NICE's evidence review also notes a real-world adoption barrier: active B12 testing costs about £18 per test in the NHS system, against roughly £2 for total B12, which is one reason it hasn't displaced total B12 as the default. NICE ultimately recommends either total B12 or active B12 as first-line, active B12 specifically in pregnancy, and methylmalonic acid, not holotranscobalamin, as the preferred second-line confirmatory test.

A 2024 letter in Annals of Clinical Biochemistry by Lorde and colleagues ("High serum total vitamin B12 may mask biologically active B12 deficiency") adds a specific, current data point: elevated haptocorrin can push a total B12 result into the normal range even when the transcobalamin-bound, usable fraction is low. That's the exact failure mode holotranscobalamin testing exists to catch, published as recently as 2024.

Between these two, the honest 2024-2025 picture is: the biochemical case for holotranscobalamin is well established, but the evidence that it outperforms total B12 or MMA in practice is still thin, and UK guidance reflects that by treating it as an equal first-line option rather than a superior one.

Tests often checked alongside this

Holotranscobalamin is rarely ordered in isolation. It's most often seen next to Vitamin B12 (Cobalamin), its counterpart covering absorption and deficiency causes generally; Methylmalonic Acid (MMA), a metabolic marker some sources treat as more clinically reliable than either B12 test; and Homocysteine, the other metabolic marker used the same way. Folate (Serum) is also commonly checked alongside all of these, since folate deficiency can produce overlapping blood changes.

This glossary entry is for informational purposes only and is not a substitute for professional medical advice. Read our Terms of Use.

Frequently asked questions